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Background: The transcription factor SOX11 is of diagnostic and prognostic importance in mantle cell lymphoma
(MCL) and epithelial ovarian cancer (EOC), respectively. Thus, there is an unmet clinical and experimental need for
SOX11-targeting assays with low background, high specificity and robust performance in multiple applications,
including immunohistochemistry (IHC-P) and flow cytometry, which until now has been lacking.
Methods: We have developed SOX11-C1, a monoclonal mouse antibody targeting SOX11, and successfully
evaluated its performance in western blots (WB), IHC-P, fluorescence microscopy and flow cytometry.
Results: We confirm the importance of SOX11 as a diagnostic antigen in MCL as 100% of tissue micro array (TMA)
cases show bright nuclear staining, using the SOX11-C1 antibody in IHC-P. We also show that previous reports of
weak SOX11 immunostaining in a fraction of hairy cell leukemias (HCL) are not confirmed using SOX11-C1, which is
consistent with the lack of transcription. Thus, high sensitivity and improved specificity are demonstrated using the
monoclonal SOX11-C1 antibody. Furthermore, we show for the first time that flow cytometry can be used to
separate SOX11 positive and negative cell lines and primary tumors. Of note, SOX11-C1 shows no nonspecific
binding to primary B or T cells in blood and thus, can be used for analysis of B and T cell lymphomas from
complex clinical samples. Dilution experiments showed that low frequencies of malignant cells (~1%) are
detectable above background using SOX11 as a discriminant antigen in flow cytometry.
Conclusions: The novel monoclonal SOX11-specific antibody offers high sensitivity and improved specificity in
IHC-P based detection of MCL and its expanded use in flow cytometry analysis of blood and tissue samples may
allow a convenient approach to early diagnosis and follow-up of MCL patients.
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The transcription factor SOX11 has recently been identi-
fied as a diagnostic, prognostic and/or functional antigen
in a variety of cancers including mantle cell lymphoma
(MCL) [1-6], epithelial ovarian cancer (EOC) [7,8] and
gliomas [9]. This transcription factor is a member of the
SOX protein family, which is characterized by a con-
served high mobility DNA binding domain (HMG) [9].
Of major clinical interest, the expression of SOX11 in
non-malignant tissues is limited to immature neurons [10]
and embryonic [11-13] and neural development [14,15].* Correspondence: sara.ek@immun.lth.se
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distribution, and reproduction in any mediumThis tissue-restricted expression facilitates specific iden-
tification of malignant cells in clinical samples and has
enabled the use of this target for specific diagnosis of
MCL, as shown in a number of studies [1-6]. SOX11 ex-
pression has also been reported in a fraction of other T
and B-cell lymphomas, including B- and T-cell lympho-
blastic lymphomas and a subset of Burkitt´s lymphoma
[3,16], but the most common B-cell lymphomas lack
SOX11 expression. Thus, using SOX11 as a diagnostic
marker for MCL avoids misclassification of morpholo-
gically similar CD5+ marginal zone lymphomas (MZL) or
CD23- chronic lymphocytic leukemia (CLL). In addition,
several studies suggest that SOX11 is a prognostic in-
dicator in MCL, although it remains to be confirmed
whether negative cases identify a rare indolent subtype
[4,17] or, conversely, patients with a shorter survival [2].tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Western blot and flow cytometry based evaluation of
SOX11-C1 antibody. (a) WB analysis revealed a single band at
predicted size in SOX11 positive compared to negative cell lines.
(b) Flow cytometry analysis using SOX11–C1 monoclonal antibody
showed specific staining of SOX11 positive compared to negative
cells lines over a range of concentrations.
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ce and identifies a subgroup of patients with improved
recurrence-free survival [7] and may also identify an
histological subtype of EOC [8]. Finally, we have re-
cently published data, demonstrating a growth regula-
tory role for SOX11 in in-vitro models of MCL [18] and
EOC [8], which was further confirmed using xenotrans-
plants in mice [19]. Together these data suggest a key
growth regulatory role of SOX11 in these neoplasms and
emphasize the need for functional antibodies for experi-
mental use in various technologies, including imaging and
flow cytometry applications.
Polyclonal antibodies targeting SOX11 have been widely
used in immunohistochemistry on paraffin sections (IHC-P)
[2,3,5,7,8,16]. However, batch to batch variations of com-
mercially available reagents have prevented routine clinical
use where standardized protocols are a prerequisite. Fur-
thermore, there is increasing desire for expanded use of
flow cytometry in immunoprofiling of tumors. This tech-
nology has already been used for several decades to con-
firm B cell clonality and characterize the phenotype of
cellular constituents in aspirates and sections of lympho-
proliferative disorders [20]. Although rarely used as the
sole tool for diagnosis, studies have shown that flow cyto-
metry is both a sensitive and specific method to identify,
and in many cases, classify B cell lymphomas [21]. In
contrast to IHC, flow cytometry enables quantitative mea-
surements at the single cell level and provides the ability
to analyze and quantify the co-expression of proteins in
defined subpopulations, in a manner superior to immu-
nohistochemistry [22]. However, reagents targeting SOX11
in flow cytometry have until now been lacking.
In this study, we demonstrate that the monoclonal
SOX11-C1 antibody enables improved use of SOX11 as a
diagnostic antigen in MCL. This antibody provides high
sensitivity and improved specificity in IHC, which has
enabled reclassification of previously positive HCL cases.
Furthermore, the SOX11-C1 antibody allowed detection
of SOX11 by flow cytometry and immunofluorescence
microscopy. To assess the potential to identify rare MCL
cells in blood through flow cytometry analysis, dilution
experiments were performed, which permitted detection
of <1% MCL cells, using SOX11 as the single discriminate
antigen. In summary, the novel SOX11-C1 antibody ful-
fills a clinical need for increased specificity in IHC-P and
extends its diagnostic utility to flow cytometry analysis.
Results
Generation and characterization of monoclonal SOX11
antibodies
Mouse monoclonal antibodies raised against a C-terminal
part of SOX11 were generated using hybridoma techno-
logy [23]. SOX11 reactivity and lack of reactivity to the
purification tag (hexahistidyl albumin binding tag, His-ABP) was assessed in ELISA and 19 clones were isolated
and subcloned. Antibody isotyping revealed a high per-
centage of clones encoding the IgM heavy chain (68%)
but clones encoding IgG could also be identified (26%
IgG1 and 5% IgG2a). Concentration of selected antibodies
(n= 5, all IgG1) were assessed and ranged between 1.6 and
4.6mg/ml.
The SOX11-C1 antibody was selected for further ana-
lysis based on superior performance in multiple appli-
cations, including identification of SOX11 protein at
predicted size in Western blot (WB) analysis (Figure 1a)
and separation of SOX11-positive (Z138) compared to
SOX11-negative (DOHH-2) cell lines over a range of con-
centrations (Figure 1b). A competitive ELISA was used to
estimate binding affinity for SOX11-C1 to approximately
0.6109 M-1. Sequencing of SOX11-C1 antibody revealed
the use of IGKV3-2*01 F, IGKJ1*01 F, IGHV1-9*01 F,
IGHD1-1*02 F and IGHJ4*01 F immunoglobulin genes
according to IMGTanalysis (www.imgt.org).Immunohistochemistry-based validation of SOX11-C1
The SOX11-C1 antibody was evaluated for routine diag-
nostic use in IHC-P. Identification of SOX11 protein
was analyzed in a range of paraffin-embedded tissues in-
cluding MCL, FL, CLL and tonsil, assembled into a TMA
Nordström et al. BMC Cancer 2012, 12:269 Page 3 of 11
http://www.biomedcentral.com/1471-2407/12/269as previously described [1]. B and T lymphoblastic lymph-
omas, HCL, Burkitt’s lymphoma and non-malignant bone
marrow were evaluated using whole tissue sections. Pa-
tient characteristics are summarized in Table 1. Primary
MCLs showed nuclear staining (Figure 2) in all fifteen
cases included in the TMA, which indicates improved
[1,16] or similar [6] sensitivity compared to previous stud-
ies. The majority of cases showed strong immunostaining
of the nucleus while four cases were moderately stained.
A single case of a previously negative MCL was assessed,
using a whole tissue section, and was confirmed to be
negative. The origin of this case was confirmed using both
immunophenotyping and multiplex PCR demonstrating
a clonal IgH-rearrangement and a 11;14 translocation.
Thus, although 100% of the cases included in the TMA
tested were positive, it is evident that rare cases of SOX11
negative MCLs occur. None of the other evaluated malig-
nant tissues, including fourteen cases of CLL, seven cases
of HCL, four cases of T- and two cases of B lymphoblastic
lymphoma showed nuclear SOX11 staining and in most
cases also lacked background cytoplasmic staining. Add-
itionally, non-malignant bone marrow (n= 5) and tonsil
sections (n= 13) showed no evidence of SOX11-specific
nuclear staining and the general background was low, in
concordance with previous data [1]. Consistent with pre-
vious findings [3,16], two of four cases of Burkitt’s lym-
phoma showed moderate nuclear staining of SOX11.
Representative SOX11 stainings of MCLs, Burkitt’s lym-
phoma and control tissues are shown in Figure 2. Of note,
previous reports where a polyclonal antibody was usedTable 1 Patient characteristics and SOX11 staining
Method Entity N (M/F)
IHC-P, TMA2 MCL 15 (12/3)
IHC-P, TMA FL 15 (7/8)
IHC-P, TMA CLL 14 (10/4)
IHC-P, WTS3 HCL 7 (7/0)
IHC-P, WTS BL 4 (2/2)
IHC-P, WTS T-lymphoblastic 4 (3/1)
IHC-P, WTS B-lymphoblastic 2 (0/2)
IHC-P, TMA Tonsil 13 (5/8)
IHC-P, WTS Bone marrow 5 (3/2)
Flow cytometry MCL 54 (2/3)
Flow cytometry FL 2 (0/2)
Flow cytometry PBMC n.a
Flow cytometry Tonsil n.a
1Number of positive (P) cases/Total number (T) of tested cases in IHC or flow cytom
2Tissue micro array (TMA).
3Whole tissue section (WTS).
4 Includes two cases of peripheral blood.
5A single previously negative case was selected, tested (WTS) and confirmed to behave suggested that a fraction of HCL cases are SOX11
positive [5,16]. However, using the novel SOX11-C1 anti-
body, none of the tested HCL cases (0/7) show nuclear
staining, which is in concordance with previous mRNA
data [1]. Reclassification of a single HCL case using
SOX11-C1 antibody is shown in Figure 2b.
Flow cytometry based validation of SOX11-C1antibody
To evaluate the performance of the SOX11-C1 antibody
in flow cytometry, eleven lymphoma and three EOC-
derived cell lines were used. All cell lines were evaluated
for SOX11 expression (Figure 3 and Table 2) and SOX11
status (positive/negative) was defined, as previously
described [18]. SOX11 positive cell lines showed strong
(Z138, GRANTA-519, SP53, JEKO-1 (all MCL) and
KM3 (Acute B lymphoblastic leukemia)), or moderate to
weak staining (REC-1 (MCL) and BJAB (Burkitt’s lymph-
oma)) by SOX11-C1 antibody (Figure 3). However,
SOX11 negative cell lines as JVM2 (MCL), MOLT-4
(Acute T-lymphoblastic leukemia), RL and DOHH-2
(both FL) generated only background signals, below the
defined cut-off, in accordance with mRNA expression
data (Figure 3 and Table 1). Fewer EOC cell lines (n = 3)
were available for analysis but showed equally clear
results. OVCAR-3 and TOV-112D were strongly stained
compared to ES-2 in accordance with mRNA expression
(Figure 3 and Table 2) and previous protein data [8].
Overall, flow cytometry analysis of SOX11 using the
SOX11-C1 antibody correlated well with SOX11 mRNA
levels and previously published WB data [18].Age range (mean) SOX11-C1 staining (P/T)1















Figure 2 IHC analysis of SOX11. (a) IHC analysis using SOX11-C1 antibody showed bright nuclear staining in 100% of MCL (TMA) cases. Most
other tissues including, B and T lymphoblastic lymphomas, FL, CLL, HCL, tonsil sections and non-malignant bone marrow show no evidence of
nuclear SOX11 staining, except Burkitt’s lymphoma where two of four cases showed moderate nuclear staining. Representative stainings of MCL
and control tissues are shown. (b) SOX11-C1 antibody enabled reclassification of previously positive HCL cases that lack SOX11 mRNA expression.
Representative staining of SOX11 polyclonal antibody and SOX11 C1 antibody is shown.
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analysis of SOX11 in tumor xenografts
The potential of the SOX11-C1 antibody to identify
human tumor cells in xenografts established in mice was
evaluated. Z138 B cell lymphoma cells were intraven-
ously injected in NSG mice, as previously described [19].
Single cell suspensions and tissue sections of paraffin-Figure 3 Flow cytometry-based assessment of SOX11 status in
cell lines. Assessment of SOX11 status using flow cytometry analysis
(bars) of B cell lymphoma and EOC cell lines reveal specific staining
in cell lines positive for SOX11, including Z138, GRANTA 519, SP53,
JEKO-1, REC-1, BJAB, KM3, OVCAR-3 and TOV-112D as assessed by
RT-PCR analysis (diamonds). For each cell line, SOX11 ΔMFI was
calculated as the difference between the mean fluorescence
intensity (MFI) from SOX11-C1 antibody and the MFI from the
control. (MFISOX11 – MFIcontrol). The relative SOX11 expression was
calculated by scaling all data to the cell line with the lowest ΔMFI
(DOHH-2).embedded tumors were analysed using SOX11-C1 anti-
body. IHC-P staining confirmed specific detection of
SOX11 in CD20-expressing human tumor cells
(Figure 4A) on a murine background. However, as
expected, tissues with a high content of murine immuno-
globulins showed extensive cross-reactivity with the sec-
ondary reagent used (data not shown). In flow cytometry,
SOX11-C1 antibody specifically stained SOX11-positive
cells compared to control cells (SOX11-knocked) after gat-
ing on human HLA-DR positive cells (Figure 4B).Immunofluorescence microscopy-based analysis of SOX11
To further assess the applicability of the SOX11-C1 anti-
body and to determine the localization of SOX11 in vitro,
fluorescence microscopy was used. Four B cell lymphoma
cell lines expressing varying amounts of SOX11 were used
and included Z138, SP53, GRANTA-519 and JEKO-1. As
expected, all four SOX11 positive MCL cell lines showed
nuclear staining of SOX11. Z138 and SP53 (Figure 5)
showed bright nuclear staining while GRANTA-519 and
JEKO-1 (Figure 5), in contrast to their flow cytometry
data, were more weakly stained. None of the negative cell
lines used, including RL and DOHH-2, showed nuclear
staining of SOX11. In addition, specific detection of
SOX11 was confirmed in OVCAR-3 (Figure 5) and TOV-
112D compared to ES-2 (Figure 5). In agreement with
flow cytometry data, OVCAR-3 showed the brightest
Table 2 Cell line characteristics and SOX11 status
Cell line Disease SOX11 status1
GRANTA-519 Mantle cell lymphoma P
JEKO-1 Mantle cell lymphoma P
JVM-2 Mantle cell lymphoma N
REC-1 Mantle cell lymphoma P
SP53 Mantle cell lymphoma P
Z138 Mantle cell lymphoma P
DOHH-2 Follicular lymphoma N
RL Follicular lymphoma N
BJAB Burkitt’s lymphoma P
KM3 MOLT-4 Acute B-lymphoblastic leukemia/lymphoma Acute T-lymphoblastic
leukemia/lymphoma
PN
ES-2 Differentiated ovarian clear cell carcinoma N
OVCAR-3 Progressive adenocarcinoma P
TOV-112D Primary malignant adenocarcinoma P
1Determined by qPCR (Positive (P) and Negative (N)) - see Methods for description (data not shown).
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visualize SOX11 in microscopy enables future experimen-
tal studies of SOX11 and co-interacting transcription fac-
tors and confirm for the first time a nuclear localization of
SOX11 also in vitro, indicating a functional use of this
transcription factor in expressing cell lines.Figure 4 Assessment of NSG mouse derived tumors. Tumors
established in NSG mice after intravenous injection of Z138 MCL
cells were analyzed for specific SOX11 expression. (A) IHC-P staining
showed a human B cell phenotype (CD20) and confirmed nuclear
staining of SOX11. (B) Flow cytometry analysis separated SOX11
positive and negative cells, derived from two separate tumors
established in NSG through injection of knocked (SOX11-) and
unknocked (SOX11+) Z138 cells.Flow cytometry analysis of SOX11 in primary
lymphocytes and malignant cells
The potential of the SOX11-C1 antibody to separate pri-
mary samples of MCL from negative non-expressing
lymphomas and non-malignant cells, using flow cytome-
try was assessed. MCL cells derived from either nodalFigure 5 Immunofluorescence analysis of SOX11.
Immunofluorescence microscopy analysis of SOX11 positive (SP53,
JEKO-1, OVCAR-2) and negative (RL, DOHH2 and ES-2) cell lines
confirm the specificity of the SOX11-C1 reagent also in imaging
applications. Representative images of bright, weak and negative
staining are shown. Imaging analysis reveals for the first time a
nuclear localization of SOX11 also in in vitro cultures.
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compared to nodal FL (N-FL) (n= 2) and non-malignant
tissues, including PBMC and tonsil. Patient characte-
ristics are summarized in Table 1. SOX11 intensities were
defined for both malignant (CD3-) and non-malignant
cells (CD3+) (Figure 6a). MCL tumor cells showed in-
creased expression of SOX11 compared to both other
lymphomas (FLCD3-) and non-malignant infiltrating cells
(MCLCD3+). This was manifested either as increased ΔMFI
(Figure 6b) or fraction of SOX11 positive cells (Figure 6c).
A cut-off value for SOX11 positivity was defined as
SOX11CD3- MFI > 700. All non-malignant tissues tested,
including PBMC (Figure 6d) and tonsil (data not shown)
were negative in agreement with previous data [18].
Furthermore, to assess the sensitivity of SOX11 as a
discriminant antigen in flow cytometry-based assays,
leukemic MCL samples were mixed with normal PBMC
(ratio MCL:PBMC; 1:0; 1:1, 1:10, 1:100, 1:000 and 0:1)
and analyzed (Figure 6d). Analysis of non-MCL popula-
tions showed that the SOX11-C1 antibody stained ≤0.3%
of the control cells. The percentage of positive cells
decreased from 65% (pure MCL) down to 48% (1:1),
15.4% (1:10), 1.6% (1:100) and 0.3% (1:1000). The data is
representative of two independent MCL donors. Using
SOX11 as a single discriminate antigen, malignant cells
were readily detected above background down to a dilu-
tion of 1:100, i.e. a population of cells containing 1.6%
MCL cells. Of note, identification of tumor cells in flow
cytometry normally requires the use of multiple markers
and advanced gating strategies, emphasizes the strength
of SOX11 as a discriminate antigen.
Discussion
SOX11 has recently been shown to have important diag-
nostic and prognostic value in MCL, EOC and glioma
[1-5,7,8,24]. As the expression of SOX11 is restricted to
immature neurons in the healthy adult [10], specific detec-
tion of SOX11 positive malignant cells is feasible using
IHC-P in most tissues. However, previous reports, where a
polyclonal antibody was used, show cytoplasmic and nu-
clear staining of SOX11 in FL [1,3,5,16] and HCL [5,16],
respectively, despite lack of SOX11 transcription [1].
Considerable efforts are needed to standardize anti-
bodies for clinical use in IHC-P. Reproducible detection of
a specific antigen is dependent on multiple parameters, in-
cluding type and concentration of fixative, incubation
time, antigen retrieval, antibody concentration and detec-
tion system [25-27]. This is exemplified by the limited
availability of antibodies targeting SOX11 in IHC-P; only
two out of more than thirty commercially available anti-
bodies targeting SOX11 can be successfully used in IHC-P
[1,2,5,7,8,16,28]. Furthermore, batch to batch variation of
polyclonal antibodies is a concern, and has limited the
routine clinical use of SOX11.To overcome these limitations, we developed a mo-
noclonal antibody raised against a C-terminal peptide of
SOX11, p-SOX11c-term, which has no homology to the
closely related protein SOX4 [29]. This feature mini-
mizes the possibility of cross-reactivity to SOX4 in B and
T lymphocytes, which would compromise analysis of
SOX11 in complex tissues. Monoclonal antibodies, such
as the SOX11-C1 antibody, are consequently of great im-
portance since they offer single epitope specificity and no
batch to batch variation. Additionally, a hybridoma clone
in murine or hamster cell lines enables large-scale produc-
tion at low cost, as recently reviewed by Yamada [30].
We show, using the monoclonal SOX11-C1 antibody,
that 100% of the MCL cases (TMA) tested presented nu-
clear staining of SOX11, suggesting a disease-defining
property. This is in accordance with recent reports, in
which SOX11 also was shown to identify rare cases of
cyclin D1-negative MCLs with either typical [3] or blas-
toid [6] morphology. However, the rare occurrence of
SOX11 negative cases, was confirmed in a single MCL
case, defined by 11;14 translocation and immunopheno-
typing. Future investigations using large, well-defined
patient series will provide reliable statistics on the infre-
quent occurrence of SOX11-negative MCLs. Of interest,
several cases of bone marrow biopsies of HCL with pre-
viously weak nuclear staining [16] where reclassified as
negative, in accordance with their lack of mRNA. Thus,
this novel monoclonal SOX11-specific antibody shows
high sensitivity and improved specificity in IHC-P, em-
phasizing its value in diagnosis and follow-up. However,
future studies are needed to determine the frequency of
SOX11 positive cases among primary Burkitt’s and T-
and B lymphoblastic lymphomas.
As previously discussed, flow cytometry has emerged
as an important clinical tool in the diagnosis and follow-
up of patients after treatment. Also for intracellular anti-
gens such as cyclin D1, successful detection of tumor
cells has been shown in >90% of cases with blood in-
volvement [31]. However, to enable assessment of cyclin
D1 overexpression in patient samples, highly standar-
dized procedures are required [32]. To determine
whether the SOX11-C1 antibody allow intracellular de-
tection of SOX11 in flow cytometry, we performed a
proof-of-principle assay and analyzed well-defined lym-
phoma and EOC cell lines. In agreement with mRNA
expression and previous WB data [18], SOX11 positive
cell lines where distinguished from negative ones in all
cases, which implies high specificity and sensitivity of
flow cytometry analysis of SOX11. Of note, SOX11 was
detected in KM3, an acute B lymphoblastic leukemia cell
line, and support previous findings of SOX11 positive B
lymphoblastic lymphomas using IHC-P [16]. Also in a
more complex setting, using a single cell suspension
derived from a tumor established by intravenous injection
Figure 6 (See legend on next page.)
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Figure 6 Flow cytometry-based assessment of the detection sensitivity of SOX11 in primary MCL cells. Flow cytometry-mediated analysis
of SOX11 (a) showed that MCL cells were specifically stained compared to infiltrating T cells (MCLCD3+) and SOX11-negative malignant cells
(FLCD3-). The specificity of the staining was assessed by comparing (b) the relative Δ MFI and (c) the fraction of SOX11 positive cells for each
patient sample. Both nodal and leukemic cases of MCL were separated from FL using the SOX11 staining. (d) The sensitivity of the SOX11
staining was estimated by diluting (1:1, 1:10. 1:100 and 1:1000) L-MCL cells in PBMC.
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distinguish SOX11-positive from negative samples.
To evaluate the potential clinical use of flow cytometry
in patients with disseminated SOX11-positive disease,
dilution experiments where performed. We demonstrate
that malignant cells, comprising as little as 1% of the total
lymphocyte population are detectable, using SOX11 as the
sole discriminant antigen. Future attempts to replicate
these findings in patients with various degree of dissemi-
nated disease and in combination with immunopheno-
typing would be of great interest. In combination, the
simplicity of the flow cytometry protocol and the disease-
defining property of the SOX11 antigen suggest its future
use in both routine diagnostics and for detection of circu-
lating tumor cells during patient follow-up. For potential
assessment of minimal residual disease, careful compari-
son with IGH-PCR needs to be performed as, flow cyto-
metry has shown to be inferior to IGH-PCR at follow-up
after treatment [33]. This difference in sensitivity may be
partly related to the clearance of B cells upon rituximab
(anti-CD20) treatment, thereby increasing the relative sen-
sitivity of IGH-PCR based detection.
Conclusions
There is an unmet clinical and experimental need for
specific and sensitive analysis of SOX11 in relation to
SOX11-positive tumors, including MCL and EOC. The
novel SOX11 monoclonal antibody, SOX11-C1, offers
improved functionality, such as (i) immunofluorescence-
based investigations (ii) improved specificity in IHC-P,
enabling more sensitive and specific diagnosis and (iii)
flow cytometry-based detection, which is potentially
feasible in aspirates from MCL and for detection of cir-
culating tumor cells.
Methods
Generation of monoclonal antibodies targeting SOX11
A C-terminal peptide of SOX11 (Table 3), referred to as
p-SOX11c-term and previously defined in the Human Pro-
tein Resource project [16,34], was used as immunogen.




1Sequence was originally derived from the HPR project as previously described [35]produced by fusion of splenocytes and mouse myeloma
SP2/0 cells, using standard procedures [23]. Heavy-chain
immunoglobulin use, antibody production and SOX11 re-
activity was assessed in 2800 individual clones, using
ELISA. Antibodies were purified on protein A columns
from culture supernatants. Concentrations were deter-
mined at OD280 and purity was assessed on SDS-PAGE.
Subcultivation of cell lines and assessment of SOX11
mRNA expression
A number of lymphoma/leukemia and EOC cell lines,
including Z138, GRANTA-519, JEKO-1, SP53, REC-1,
JVM-2, RL, DOHH-2, BJAB, KM3, MOLT-4, ES-2,
OVCAR-3, and TOV-112D, were purchased from ATCC
or DSMZ (or when not available, received as kind dona-
tions, see acknowledgement). Lymphoid cell lines were
cultured in RPMI-1640 (Thermo Scientific HyClone,
Logan, UT, USA) supplemented with 10% fetal bovine
serum (Invitrogen, San Diego, CA, USA) and 2 nM L-
glutamine (Invitrogen). EOC cell lines where cultured in
either McCoy’s (Thermo Scientific HyClone) + 10% FBS
and 2 mM L-glutamine (ES-2), DMEM high glucose
(Thermo Scientific HyClone) + 10% FBS and 2 mM L-
glutamine (TOV-112D) or RPMI-1640+ 20% FBS+2
mM L-glutamine + 0.01 mg/ml insulin (Sigma-Aldrich)
(OVCAR-3). All cell lines were kept under standard con-
ditions (5% CO2, 37°C). The relative quantity (RQ) of
SOX11 mRNA in these cell lines was measured with real
time-quantitative PCR (RT-PCR), as previously described
[18]. The RQ is calculated as 2-(ΔΔCT(SOX11-GAPDH)) and
cell lines with a ΔCT (SOX11+RT, SOX11-RT) > |2| were defined
as SOX11 positive. Error bars have been calculated using
the standard error value with 95% confidence interval.
Evaluation of the SOX11-C1 antibody in Western blot
using B cell lymphoma cell lines
Protein lysate (30 μg) obtained from B cell lymphoma cell
lines were run on a NuPAGE 10% Bis-Tris gel (Invitrogen).
Proteins were blotted onto a PVDF membrane with the
iBlotW Dry Blotting System (Invitrogen) and the mem-
brane was blocked in 5% milk/PBS. SOX11 expressionDDELQLQIKQEPDEEDEEPPHQQLLQPPGQQPSQLLRRYNVAKVPASPTLSSSAES
RAGATSGAGGGSRLYYSFKNITKQHPPPLAQPALSPASSRSVSTSSS
.
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1 μg/ml in 5% milk/PBS. A primary antibody targeting
GAPDH was used as loading control and a HRP labeled
rabbit anti-mouse antibody (Dako, Glostrup, Denmark)
was used for detection. Labeled proteins were visualized
using SuperSignal West Femto Max Sensitivity Substra-
te (Pierce Biotechnology, Rockford, IL, USA), and images
retrieved using a CCD camera (FluorSMax, Biorad).
Proteins were quantified, using the Volume Rect Tool
(Quantity One, Biorad), and the relative volume of the
background was set to 1.
Flow cytometry analysis of SOX11 in B cell lymphoma
and EOC cell lines
Lymphoma/leukemia and EOC cell lines were fixed in
4% paraformaldehyde (PFA) (Thermo Scientific) for 10
minutes. The cells were subsequently permeabilized in
PBS supplemented with 5% FCS and 0.5% Triton X-100
(Sigma Chemical Co., St Louis, USA). SOX11 was stained
using SOX11-C1 antibody at 1 μg/ml for 16 h. Primary
antibody and unstained control cells were detected using
goat anti-mouse-APC (BD Bioscience, San Jose, CA,
USA). All samples were analyzed on FACS Canto II (BD
Bioscience) and FCS Express 4 Flow Research Edition (De
Novo Software, Los Angeles, CA USA) was used for data
analysis.
Sequencing of immunoglobulin genes coding for the
SOX11-C1 antibody
The immunoglobulin genes coding for SOX11-C1 were
sequenced in both heavy and light chain variable regions
(VH, VL) according to standard procedures (Absea Bio-
technology Ltd, Beijing, China).
Immunohistochemistry analysis using SOX11-C1 antibody
SOX11-C1 monoclonal antibody was tested on a tissue
microarray (TMA) consisting of fifteen MCL, fourteen
CLL, fifteen follicular lymphomas (FL), two Burkitt’s
lymphomas and thirteen tonsil sections. Additionally,
whole sections of one MCL, two Burkitt’s lymphomas,
seven HCL, two B-lymphoblastic lymphomas, four T-
lymphoblastic lymphomas and five normal bone mar-
rows were tested. Tumors developing after intravenous
injection of Z138 in NOD SCID gamma (NSG) mice
were prepared, as previously described [19]. Bone mar-
row biopsies from HCL were fixed in 10% formalin and
decalcified until softened in a solution of ethanol, nitric
acid and chromium trioxide at room temperature, while
bone marrows obtained from healthy donors or B-
lymphoblastic lymphomas were decalcified in a solution
of EDTA at 37°C. All samples were routinely processed
and embedded in paraffin for tissue conservation. Anti-
gen retrieval was performed using the PT-LINK system
(Dako) at pH 9. Staining was performed using SOX11-C1 (1-2ug/ml). For detection, Envision + System HRP
(Dako) was used on a DAKO autostainer Plus (Dako).
Staining of a single HCL case using a polyclonal reagents
targeting SOX11, was performed as previously described
[3,16].
Affinity estimations using competitive ELISA
The affinity of the SOX11-C1 antibody to its antigen
was estimated, using a competitive setup in ELISA.
Briefly, a high binding microtiter plate was coated with
p-SOX11c-term (10 ng/well). After blocking, a fixed con-
centration of SOX11-C1 (0.1 μg/ml) was pre-incubated
with the antigen, p-SOX11c-term, at an optimized concen-
tration range (0–100 nM) for 1 hour. The amount of un-
bound antibodies in solution was measured with ELISA.
The dissociation constant (KD) was estimated to equal the
antigen concentration at 50% signal inhibition.
Image analysis of SOX11 using fluorescence microscopy
Slides for image analysis were prepared by (i) immo-
bilization of lymphoma cells (40,000 cells/slide) onto a
glass slide, using a cytospin (Shandon, Pittsburgh, USA) or
(ii) cultivation of EOC cells in eight-well chamber slides
(Nalge Nunc International, Rochester, NY, USA). Cells
were fixed in 4% PFA for 10 min followed by per-
meabilization (PBS supplemented with 5% FCS and 0.5%
Triton X-100, (Sigma Chemical Co)). Cells were stained
with SOX11-C1 antibody (1 μg/ml, overnight) followed by
a goat anti-mouse IgG-ALEXA 568 reagent (Invitrogen).
The nuclei were counterstained with DAPI (Invitrogen/
Dynal) and mounted with Pro Long Gold anti-fade
medium (Invitrogen). Images were captured (exposure
time; DAPI 40 ms, TX RED 2 s) using a fluorescence
microscope (Nikon Eclipse 80i, Nikon Instrument Inc.
NY, USA) equipped with Nis Element BR (Nikon).
Flow cytometry analysis of SOX11 in NSG mice-derived
tumors
Tumors were established in female NSG mice (The Jackson
Laboratory, Sacramento, California, USA, (bred at Lund
University for multiple generations)) by intravenous injec-
tion of Z138 cells (0.5 × 106 cells) carrying SOX11-specific
(SOX11-knocked) or scrambled (control) shRNA sequen-
ces. Animals were sacrificed when presenting symptoms of
disease, as previously described [18]. All animal experimen-
tation was strictly performed in accordance with the regu-
lations of the Lund University Ethics Committee (Dnr
M229-09).
Single cell suspensions from tumors developing in the
ovaries were prepared. Cells were stained in two separate
tubes, i.e., (i) extracellular with HLA-DR-APC (BD Bios-
ciences) or (ii) stained with SOX11-C1 after fixation and
permeabilization, as described above. FSC and SSC gat-
ing strategy was based on HLA-DR positive cells as a
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used to assess SOX11 expression in the complex mix-
ture of cells.
Flow cytometry analysis of SOX11 in primary B cell
lymphomas
Peripheral blood mononuclear cells (PBMC) from two
leukemic MCL (L-MCL) patients and two non-malignant
blood donors were isolated by Ficoll (VWR) gradient cen-
trifugation, according to standard procedures. Further-
more, single-cell suspensions from three MCL, two FL,
and two non-malignant tonsil biopsies were prepared by
dissection of tissue, with resultant diffusion of malignant
cells into the media (RPMI-1640). Malignant cells (L-
MCL) were mixed with PBMC at the following ratios; 1:0
1:1, 1:10, 1:100, 1:1000 and 0:1. For each sample, 500,000
cells were stained with SOX11-C1 antibody as described
above but with the following modifications: after addition
of goat anti-mouse-APC the samples were blocked with
mouse IgG (Jackson ImmunoResearch Laboratories Inc.,
West Grove, PA, USA) for 30 minutes followed by stain-
ing with CD3-PE (Invitrogen) and CD20-FITC (Dako).
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